The COVID-19 pandemic has provided US regulators with a unique opportunity to test whether they can successfully use remote monitoring to evaluate the performance of firms making software as a medical device (SaMD). So far, it seems it is a viable option, a new report says.
The US Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) published a report on 14 September updating stakeholders of the progress it’s made with its Precertification...